<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134328">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01704079</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-3002</org_study_id>
    <nct_id>NCT01704079</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CTAP101 Capsules for Treatment of SHPT and Vitamin D Insufficiency</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytochroma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytochroma Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact
      parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and
      tolerability of CTAP101 will also be evaluated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 210 stage 3 or 4 CKD subjects with SHPT and vitamin D insufficiency will be
      randomized to either CTAP101 Capsules or matching placebo for 6 months of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes of at least 30% in plasma iPTH from pretreatment baseline</measure>
    <time_frame>Baseline and  6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary Objectives:
The primary objectives of this study are:
To evaluate the efficacy of CTAP101 Capsules versus placebo in reducing plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in safety and tolerability to CTAP101 capsules</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate the safety and tolerability of CTAP101 Capsules through changes in adverse events, physical examinations,vital signs, clinical laboratory tests, vital signs, and 12-lead ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum total 25D to ≥ 30 ng/ML</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of CTAP101 capsules versus placebo in increasing serum total 25D to ≥ 30 ng/ML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hypercalciuria, hypercalcemia and drug-related hyperphosphatemia.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in efficacy and safety based on weight, age, gender, race, dose, CKD stage, SHPT severity, use of Vitamin D supplements, use of Ca supplements, baseline serum total 25D and eGFR</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Secondary Hyperparathyroidism (SHPT)</condition>
  <condition>Vitamin D Insufficiency</condition>
  <arm_group>
    <arm_group_label>CTAP101 30 μg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 CTAP101 30 μg capsule daily at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 60 μg capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 CTAP101 30 μg capsules daily at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 30 μg sugar pill capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 CTAP101 sugar pill capsule daily at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 60 μg sugar pill capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 CTAP101 30 μg sugar pill capsules daily at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 30 μg capsules</intervention_name>
    <description>Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.</description>
    <arm_group_label>CTAP101 30 μg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 60 μg capsules</intervention_name>
    <description>Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.</description>
    <arm_group_label>CTAP101 60 μg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 30 μg sugar pill capsule</intervention_name>
    <description>Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.</description>
    <arm_group_label>CTAP101 30 μg sugar pill capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTAP101 60 μg sugar pill capsules</intervention_name>
    <description>Subjects will take 1 capsule (CTAP101 30 μg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.</description>
    <arm_group_label>CTAP101 60 μg sugar pill capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Urinary albumin excretion ≤ 3000 mcg/mg of creatinine

          2. Stage 3 or 4 CKD

          3. Plasma iPTH: ≥ 85 pg/mL and &lt; 500 pg/mL

          4. Serum Ca: ≥ 8.4 mg/dL and &lt; 9.8 mg/dL

          5. Serum P: ≥ 2.0 mg/dL and &lt; 5.0 mg/dL

          6. Serum 25-hydroxyvitamin D: ≥ 10 ng/mL and &lt; 30 ng/mL.

          7. Stable dose of Vitamin D therapy ≤ 1600 IU/day and receiving same dose for at least 2
             months

        Exclusion Criteria:

          1. History of kidney transplant or parathyroidectomy

          2. Spot urine calcium:creatinine ratio &gt; 0.2 (&gt;200 mg/g Cr)

          3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event
             or hepatitis

          4. Currently on dialysis

          5. Use of pharmacological dose of ergocalciferol or cholecalciferol (≥ 50,000 IU mcg per
             month) during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytochroma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cytochroma Inc.</name>
      <address>
        <city>Bannockburn</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>October 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parathyroid Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Kidney Failure, Chronic</keyword>
  <keyword>Hyperparathyroidism, Secondary</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
